Pexelizumab Reduces Mortality in High Risk Coronary Artery By-Pass Patients

Pexelizumab Reduces Mortality in High Risk Coronary Artery By-Pass Patients

14/03/2006

Peter Smith, Duke University Medical Center, Durham, NC Late Breaking Clinical Trials, ACC Atlanta 2006, Sunday 12th March 2006 The drug pexelizumab, targeting inflammation, reduced the risk of death

Peter Smith

Peter Smith, Duke University Medical Center, Durham, NC
Late Breaking Clinical Trials, ACC Atlanta 2006, Sunday 12th March 2006
The drug pexelizumab, targeting inflammation, reduced the risk of death among patients about to have coronary artery by-pass grafting in the PRIMOCABG-II study. Peter Smith of Duke University told the ACC about his group’s findings. [audio:https://www.audiomedica.com/podcasting/acc2006/peter_smith.mp3]